Stay updated on GM T-cell Therapy in AML/BPDCN Clinical Trial
Sign up to get notified when there's something new on the GM T-cell Therapy in AML/BPDCN Clinical Trial page.

Latest updates to the GM T-cell Therapy in AML/BPDCN Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe clinical trial record for CD123-directed CAR T-cell therapy in acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm is displayed, including study design, participant criteria, and outcome measures.SummaryDifference69%

- Check15 days agoChange DetectedThe ClinicalTrials.gov page’s footer revision changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden message instead of the study record.SummaryDifference0.2%

- Check22 days agoChange DetectedThe record now presents details of a phase I CD123 CAR T-cell immunotherapy study, including its treatment plan, eligibility criteria, outcome measures, collaborators, and current recruitment status.SummaryDifference71%

- Check29 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check36 days agoChange DetectedThe footer’s site revision changes from v3.7.0 to v3.7.1, while the 403 error page remains otherwise unchanged.SummaryDifference0.2%

- Check57 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study details, with a minimal header/footer visible, indicating the content is currently inaccessible.SummaryDifference22%

Stay in the know with updates to GM T-cell Therapy in AML/BPDCN Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GM T-cell Therapy in AML/BPDCN Clinical Trial page.